Videos

Cilta-cel improved outcomes for patients with lenalidomide-refractory functional high-risk multiple myeloma vs standard of care, according to data presented by Luciano Costa, MD, at the 2024 ASCO Annual Meeting.

Maria-Victoria Mateos, MD, PhD, presents results from the phase 3 DREAMM-7 trial, which demonstrated the efficacy of belantamab mafodotin plus bortezomib and dexamethasone as a potential new standard of care for patients with R/R MM.

Rebecca Shatsky, MD, shares results on datopotamab deruxtecan plus durvalumab for certain patients with advanced breast cancer from the I-SPY2.2 trial.

Robert Rifkin, MD, discusses results from a phase 2 study that evaluates outpatient step-up administration of teclistamab among patients with relapsed/refractory multiple myeloma.

David Andorsky, MD, shares expert insight on the significance of clinical trials in lymphoma research, focusing on the inclusion of older patients in these studies.

John Burke, MD, discusses some of the most compelling topics in diffuse large B-cell lymphoma and mantle cell lymphoma research presented at the 2024 ASCO Annual Meeting.

Xichun Hu, MD, PhD, Fudan University Cancer Institute, Shangai, China, discussed results from the DESTINY-Breast06 trial which identified trastuzumab deruxtecan as a potential new standard of care for patients with HER2-Low metastatic breast...

Don Dizon, MD, discusses the results from the phase 2 BrUOG 354 trial evaluating nivolumab with/without ipilimumab among patients with ovarian and extra-renal clear cell carcinoma.

Jane Meisel, MD, discussed results from the I-SPY 2.2 trial which investigated the clinical activity of datopotamab deruxtecan among patients with HR-positive, HER2-negative breast cancer.

David Andorsky, MD, discussed results from the phase 2 EPCORE NHL-6 trial, which showed that patients with R/R DLBCL and FL who were treated with subcutaneous epcoritamab demonstrated positive results in the outpatient setting.